Trial record 3 of 4 for:    Flaxseed | NCCAM

Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics (FABrC)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
AstraZeneca
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT00612560
First received: February 7, 2008
Last updated: October 8, 2013
Last verified: October 2013
  Purpose

The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the effect of combined flaxseed and aromatase inhibitor therapy on breast cancer treatment. Because of the increasing use of both complementary and alternative approaches to treatment, and the use of aromatase inhibitors in the treatment of breast cancer, the proposed study has potential to provide important clinical information about the effect of foods high in phytoestrogens on a common endocrine therapy used in breast cancer.


Condition Intervention Phase
Breast Cancer
Drug: Anastrozole
Dietary Supplement: flaxseed
Drug: Placebo
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis

Resource links provided by NLM:


Further study details as provided by Roswell Park Cancer Institute:

Primary Outcome Measures:
  • tumor characteristics, proliferation and apoptosis, ER, PR, HER2 expression [ Time Frame: biopsy and surgical resection ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • steroid and growth hormone serum levels [ Time Frame: biopsy and surgical resection ] [ Designated as safety issue: No ]

Enrollment: 28
Study Start Date: November 2007
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 2
Flaxseed 25 mg per day and 1 placebo pill per day
Dietary Supplement: flaxseed
25 g per day ground
Experimental: 3
25 mg flaxseed per day and 1 mg anastrozole pill per day
Drug: Anastrozole
1 mg per day
Other Name: Arimidex
Dietary Supplement: flaxseed
25 g per day ground
Placebo Comparator: 4
Placebo pill 1 per day
Drug: Placebo
Placebo pill 1 per day
Experimental: 1
Anastrozole 1 mg pill per day
Drug: Anastrozole
1 mg per day
Other Name: Arimidex

Detailed Description:

Although the 10 year survival rate for women with early stage breast cancer is very good, distant recurrence is still a serious concern, especially for estrogen receptor positive women. Consequently, breast cancer survivors are interested in therapies that might improve their recurrence free survival (RFS). Used in postmenopausal women, aromatase inhibitors (AI) block the peripheral conversion of androgens to estrogen, effectively lowering the estradiol available to promote breast tumor proliferation. However, use of AIs is associated with hot flashes, joint pain, bone loss, and an increase in cardiac events. Furthermore, many breast tumors eventually develop resistance to hormonal treatments. Complementary and alternative medicines (CAMs) are widely used by cancer survivors in an attempt to reduce disease recurrence with fewer side effects and potential health benefits, and use is particularly prevalent among breast cancer survivors. Flaxseed (FS) is a commonly available food often consumed as a dietary supplement and is the richest food source of lignans, a phytoestrogen. In experimental models, flaxseed consumption has been shown to exhibit a number of activities that suggest a potential benefit of flaxseed in the adjuvant setting. However, the majority of human studies investigating the biologic effects of flaxseed have involved healthy women. There is a paucity of clinical data regarding the efficacy and safety of use of flaxseed among women with breast cancer, especially among those receiving AIs. Because the phytoestrogens in flaxseed can influence many of the same biologic pathways affected by hormonal agents, diet-drug interactions are possible. Additionally, it is possible flaxseed could act through growth and signaling pathways, modifying the development of endocrine resistance. Potential synergistic or antagonistic effects between flaxseed and antiestrogens are of particular interest given the increasing use of AIs to treat postmenopausal women with hormone responsive disease. We propose to conduct a pilot 2x2 factorial randomized intervention study between tumor biopsy and resection, in postmenopausal women diagnosed with ER positive breast cancer, to assess the effects of flaxseed and AI on a number of steroid hormone and tumor-related characteristics associated with long-term survival, and to investigate the potential interaction between flaxseed and AI on tumor expression of Ki-67, caspase, ERα, ERβ, PgR, HER2, IGF1, IGFIR. The pre-surgical setting offers a unique opportunity to rapidly obtain information on intervention related effects on growth factor and signaling pathways related to tumor characteristics in a short time period without the interference of other treatments. We hypothesize that both flaxseed and AI interventions will independently favorably affect growth factor and signaling pathway protein expression resulting in reduced tumor proliferation and increased apoptosis. We further hypothesize that these improvements will be reflected in improved recurrence scores as estimated by the Mammostrat antibody panel (Applied Genomics Incorporated). The proposed study will provide important clinical data for future dietary intervention studies involving phytoestrogen lignans from flaxseed.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 and ≤ 85 years
  • Postmenopausal status defined as: no menstrual cycle in the past 12 months hysterectomy with bilateral oophorectomy hysterectomy with intact ovaries if age > 55 years
  • Newly diagnosed with incident, primary, invasive, estrogen receptor positive clinical stage II or lower breast cancer
  • ECOG performance status of 1 or less
  • Willingness to comply with study guidelines and procedures
  • Willingness and ability to provide informed consent
  • Usual consumption of soy no more than 1 time per week and willingness to avoid whole soy foods or concentrated soy sources (soy milk, tofu, substitute meat products, meal replacement bars) during the intervention period
  • Willingness to avoid herbal and dietary supplements (not including vitamins), aspirin, and ibuprofen during the intervention period
  • No competing neoadjuvant or chemotherapy treatment
  • Time between pre-surgical visit and surgery must be at least 2 weeks
  • No chemotherapy in the past 12 months

Exclusion Criteria:

  • Inability to read and write English
  • Previous invasive breast cancer
  • Insulin dependent Type I or II diabetes diagnosed by physician
  • History of coagulopathy, thrombocytopenia, or bleeding disorder
  • Current (past 30 days) regular (at least once per week) use of reproductive hormone therapy, Tamoxifen, aromatase inhibitors, or other estrogen inhibitors, flaxseed, or antibiotics
  • Current chemotherapy or neoadjuvant chemotherapy
  • Allergies to flaxseed, nuts, or other seeds
  • Renal dysfunction defined as creatinine > 1.5 mg/dl
  • History of Crohns' disease, ulcerative colitis, irritable bowel syndrome, celiac sprue, or other malabsorption syndrome, diverticulitis, diverticulosis, or other bowel diagnosis which, in the opinion of the breast surgeon, would contraindicate large doses of dietary fiber or would impair nutrient absorption
  • Current, regular (more than once weekly) use of prescription blood-thinning agents including coumadin, heparin and heparin related drugs, clopidogrel bisulfate
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00612560

Locations
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Roswell Park Cancer Institute
AstraZeneca
Investigators
Principal Investigator: Tracey L O'Connor, MD Roswell Park Cancer Institute
  More Information

No publications provided

Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT00612560     History of Changes
Obsolete Identifiers: NCT00635908
Other Study ID Numbers: I 99507, I99507, R21AT004024-01
Study First Received: February 7, 2008
Last Updated: October 8, 2013
Health Authority: United States: Food and Drug Administration
United States: Federal Government

Keywords provided by Roswell Park Cancer Institute:
breast neoplasms
phytoestrogens
tumor characteristics
proliferation
apoptosis
estrogen receptor
HER2

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Anastrozole
Aromatase Inhibitors
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 15, 2014